SARS-CoV-2

Elevated levels of inflammatory factors may be linked to persistent COVID-19 symptoms, researchers find.

Data shows that antibodies produced as part of the COVID-19 immune response can neutralize a more transmissible variant of SARS-CoV-2.

Tracking how SARS-CoV-2 interacts with host cell receptors during infections may give us new ideas for COVID-19 drug targets.

Some neutralizing antibodies against SARS-CoV-2 may heighten lung tissue damage from COVID-19, an A*STAR study finds.

From forming protective physical barriers to stabilizing mRNA vaccines, polymers provide endless solutions to the threat of coronaviruses and other current and impending diseases.

The amount of neutralizing antibodies produced by COVID-19 patients—and the length of time they remain detectable—can vary wildly, a study suggests.

Understanding why COVID-19 tends to strike the old but spare the young could inform how to prioritize limited COVID-19 vaccines.

Four newly discovered SARS-CoV-2 peptides not only promise to make COVID-19 tests cheaper and more specific, but may also reveal disease severity.

In a classic case of double trouble, the binding of SARS-CoV-2’s spike protein to bacterial lipopolysaccharide supercharges inflammation in COVID-19 patients.

These novel immune signatures identify patients most at risk for developing severe COVID-19 symptoms.

Lockdown measures not only reduced the number of COVID-19 cases but also resulted in a temporary improvement in air quality, study finds.

Using flow cytometry, researchers have developed a sensitive and specific test for COVID-19 that can identify asymptomatic carriers.